Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04136535 | Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC(PCA) | recruiting | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06709859 | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | recruiting | Phase 2 | 30 | Shandong Public Health Clinical CenterOTHER_GOV | 1 | Jul 17, 2025 |
| clinicaltrials |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | recruiting | Phase 2 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06617936 | Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. | recruiting | Phase 2 | 36 | Hua ZhangOTHER_GOV | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06379087 | Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC | recruiting | Phase 2 | 20 | Ji YonglingOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07037680 | Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT | recruiting | Phase 2 | 44 | JIANYANG WANGOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06987734 | Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients | recruiting | Phase 2 | 25 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05623319 | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)(THOR) | recruiting | Phase 2 | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034326 | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 405 | Kong FanmingOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034391 | A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status | recruiting | Phase 2 | 40 | China Medical University, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06276283 | DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) | recruiting | Phase 2 | 60 | Dizal PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06205927 | Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 77 | Jian ChenOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06775678 | Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 84 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05613452 | Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311981 | Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients | recruiting | Phase 2 | 29 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04952480 | Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer(DARTS) | recruiting | Phase 2 | 31 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05765877 | Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 26 | Pingping SongOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06924398 | Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）(ARMOR2501) | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06929936 | Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC(PROTECT-1) | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06977074 | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC(PROPHET) | recruiting | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06343064 | Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI(KYLIN-1) | recruiting | Phase 1 / Phase 2 | 156 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06574347 | Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.(KYLIN-2) | recruiting | Phase 2 | 120 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06659042 | Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | Shanghai Chest HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05631249 | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C(CODEBREAK-IGR) | recruiting | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06498986 | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | recruiting | Phase 2 | 25 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06939127 | Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC | recruiting | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06754930 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03290534 | Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet® | recruiting | Phase 2 | 40 | CivaTech OncologyINDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911606 | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 45 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06896890 | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 32 | Inhatarget TherapeuticsINDUSTRY | 3 | Mar 26, 2025 | clinicaltrials |
| NCT06663098 | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).(CARRY-ON) | recruiting | Phase 2 | 142 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06730295 | Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06863506 | Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC | recruiting | Phase 2 | 78 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04777084 | The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06849167 | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC | recruiting | Phase 2 | 63 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05281406 | Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | recruiting | Phase 2 | 50 | Goethe UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | recruiting | Phase 1 / Phase 2 | 24 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06714708 | Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC | recruiting | Phase 2 | 86 | Anhui Provincial Cancer HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06793813 | Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 44 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2025source: clinicaltrials